Drugs Made In America Acquisition II Corp. (DMII)
Nasdaq · Financial Services · Shell Companies
$10.190.00%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $649M
- P/E (trailing)
- 34.0
- 52-week range
- $9.86 – $10.33
- 52-week change
- +3.14%
- EPS (trailing)
- $0.30
Fiscal year to Dec 2025
- Net income
- $4.2M
From the company’s annual report on SEC EDGAR.
About Drugs Made In America Acquisition II Corp.
Drugs Made In America Acquisition II Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. It intends to source and evaluate companies focused on the pharmaceutical sector. Drugs Made In America Acquisition II Corp. was incorporated in 2024 and is based in New York, New York.
Headquarters: New York, United States